Interesting CLL date from Medscape

[Petroc]

Probably ‘old hat’ for the likes of Neil, et al,(Jan 23) but some may find it of interest re improved responses to new therapies & drug / BTK combinations.

medscape.com/recap/981802

[DRM18]

The link brought me to a log-in page.

Any summary you can offer?

--Dave!

[Petroc in reply to DRM18]

Hi Dave, the gist of it is all good news. Basically survival outcomes are now approaching those in the general population in terms of life expectancy. What follows is the final section of the article for more refractory forms of CLL.

Another study focused on the triple combination of acalabrutinib, venetoclax, and obinutuzumab in treatment-naive patients with high-risk disease for whom the latter two therapies proved suboptimal. The triple combination delivered durable responses in this group.Next, Dr Burger turns to a long-term pooled analysis of patients aged 65 years or older who were treated with ibrutinib in the first-line setting. The study compared survival among these patients vs age-matched persons without CLL in the general population and found comparable survival in these two groups.In relapsed/refractory disease, Dr Burger discusses pirtobrutinib, an emerging Bruton tyrosine kinase inhibitor (BTKi), which demonstrated efficacy in heavily pretreated patients regardless of prior therapy, reason for discontinuation of previous therapy, or mutation status.He closes by examining results for the second-generation BTKi zanubrutinib showing superior progression-free survival compared with the first-generation agent ibrutinib in the phase 3 ALPINE study.